Sign in
IB

IOVANCE BIOTHERAPEUTICS, INC. (IOVA)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 total product revenue was $59.95M, up 22% q/q and 93% y/y, driven by Amtagvi ($54.1M; 102 commercial patients) and Proleukin ($5.9M) .
  • The quarter missed Street consensus on revenue and EPS; revenue of $59.95M vs $67.14M* and EPS of -$0.33 vs -$0.276*; management reiterated FY25 revenue guidance of $250M–$300M .
  • Gross margin (excl. non-cash items) was 31%; a strategic restructuring targets >$100M annual cost savings from Q4 2025 and lowers next-4-quarters net cash burn to < $245M, extending runway into Q4 2026 .
  • Catalysts: specialty pharmacy channel with McKesson to unlock community access , Health Canada approval (NOC/c) for Amtagvi on Aug 18, 2025 , and multiple clinical data readouts in 2H 2025 .

What Went Well and What Went Wrong

What Went Well

  • “More than 100 patients treated within a single quarter,” with 102 commercial Amtagvi infusions, demonstrating accelerating adoption across ATCs and the new specialty pharmacy channel .
  • Real-world retrospective data: ORR 48.8% overall (20/41) and 60.9% in third-line or earlier, supporting earlier use narratives and community referral initiatives .
  • Manufacturing cycle-time improved to 33 days; success rates rebounded vs Q1; management expects margins to improve further as restructuring drives lower cost of sales .

What Went Wrong

  • Revenue and EPS both missed consensus; revenue $59.95M vs $67.14M* and EPS -$0.33 vs -$0.276*; cost of sales elevated at $56.66M, including $19.0M period costs tied to drop-offs and success rates .
  • EMA marketing application was withdrawn following CHMP interactions; company plans resubmission with additional analyses (e.g., virtual control arm), delaying EU commercialization .
  • R&D expense increased 28% y/y to $79.36M in Q2, pressuring the P&L despite SG&A decline y/y; net loss widened to $111.66M .

Financial Results

MetricQ2 2024Q1 2025Q2 2025
Revenue ($USD Millions)$31.106 $49.324 $59.952
Diluted EPS ($USD)-$0.34 -$0.36 -$0.33
Cost of Sales ($USD Millions)$31.368 $49.741 $56.664
Net Loss ($USD Millions)$97.101 $116.163 $111.658
Product Revenue BreakdownQ2 2024Q1 2025Q2 2025
Amtagvi ($USD Millions)$12.8 $43.6 $54.1
Proleukin ($USD Millions)$18.3 $5.7 $5.9
MarginsQ4 2024Q1 2025Q2 2025
Gross Margin % (Standard)46% 10% —
Gross Margin % (Excl. non-cash items)——31%
KPIsQ1 2025Q2 2025
Commercial patients treated (Amtagvi)85 102
U.S. ATCs in network>80 >80
Manufacturing turnaround (days)~34 33
Amtagvi price per infusion$562,000 (effective 4/1) $562,000
Proleukin wholesale restocking (2 of 3)Expected in Q2 Occurred; third later in year
Cash, cash equivalents & investments ($USD ‘000s)$359,713 $301,183

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Total Product RevenueFY 2025$450M–$475M $250M–$300M Lowered
Net Cash BurnFY 2025< $300M < $300M Maintained
Net Cash Burn (next 4 quarters)Through Q2 2026—< $245M; one-time restructuring charges < $6M New
Long-term Gross Margin TargetMulti-year>70% >70% Maintained
Proleukin Trend2H 2025Significant increase expected Strong growth expected; 3rd wholesaler later in year Maintained

Earnings Call Themes & Trends

TopicQ4 2024 (Q-2)Q1 2025 (Q-1)Q2 2025 (Current)Trend
ATC adoption & community referrals~70 ATCs; 64% infused ≥1; 13% infused ≥10; focus on community referrals 80+ ATCs; 48 infused ≥1; 11 infused ≥10; push for earlier referrals ->80 ATCs; specialty pharmacy via McKesson to serve community practices Broadening access; earlier-line use gaining momentum
Manufacturing success & turnaround34-day turnaround; capacity >1,200 patients; maintenance completed Success rates dipped; rebounded into Q2; turnaround ~34 days Turnaround improved to 33 days; further success-rate improvement Operational excellence; improving COGS trajectory
Proleukin distribution3 U.S. wholesalers activated; significant restocking 2 of 3 wholesalers to reorder in Q2; other channels contribute 2 of 3 restocked; 3rd expected later; usage consistent (0–6 doses) Restocking aligns with Amtagvi demand
Pricing & reimbursementPrice increase planned for April included in guidance; broad coverage Guidance revised; reimbursement remains strong Price at $562k; demand unaffected post-increase Price durability confirmed
Ex-U.S. regulatoryUK, EU, Canada approvals expected 2025 UK/Canada/EU pending Canada approved (NOC/c); EU MAA withdrawn; UK/Aus/CH progressing Mixed: Canada positive; EU resubmission needed
Margin/cost structureGM improving; >70% target reiterated Standard GM 10% in Q1; >70% long-term 31% GM excl. non-cash; >$100M cost saves; < $245M next-4-q burn Margin tailwind via restructuring
Pipeline milestonesTILVANCE-301, IOV-LUN-202; next-gen programs -NSCLC, endometrial data 2H25 Multiple 2H25 readouts; IOV-4001, -3001, -5001 -Clinical catalysts near-term

Management Commentary

  • “In the first half of 2025, we continued to drive U.S. adoption for Amtagvi… surpassing more than 100 patients treated within a single quarter.” — Frederick Vogt .
  • “Gross margin was 31% excluding non-cash items… [and] expected to increase significantly through near term optimization of manufacturing capacity utilization.” — Frederick Vogt .
  • “We continue to see the potential to achieve U.S. peak sales of $1,000,000,000 or more.” — Frederick Vogt .
  • “We entered… a specialty pharmacy agreement with Biologics by McKesson… another option for providers to acquire Amtagvi.” — Dan Kirby .
  • “Strategic restructuring… resulting in more than $100 million in annual cost savings… [and] net cash burn… less than $245 million” — Management .

Q&A Highlights

  • Demand and pricing: 102 infusions vs 85 last quarter; price increased to $562k effective April 1 with no demand impact .
  • Proleukin outlook: Two of three wholesalers restocked in Q2; third expected later in the year; dose patterns unchanged (0–6 per patient) .
  • Margin trajectory: Focused operational excellence and restructuring to lower cost of sales; expect margin improvement from Q3 onward .
  • EU path: EMA MAA withdrawn; plan to resubmit with additional analyses (e.g., virtual control arm); does not affect U.S. NSCLC path .
  • Community access: Specialty pharmacy enables hospitals to avoid direct purchasing burden, facilitating referrals and earlier-stage patients .

Estimates Context

MetricConsensus (Q2 2025)*Actual (Q2 2025)Surprise
Revenue ($USD)$67.14M*$59.95M — $7.19M (miss)
EPS ($USD)-$0.276*-$0.33 — $0.053 (miss)
FY 2025 Consensus*Consensus Value*Notes
Revenue ($USD)$259.85M*Within company guidance of $250–$300M
EPS ($USD)-$1.082*Reflects ongoing investment and ramp dynamics

Values retrieved from S&P Global.
Counts: Q2 revenue estimates (n=11), Q2 EPS estimates (n=9); FY25 revenue (n=11), FY25 EPS (n=9).

Where estimates may adjust: Lower EU timing and restructuring cost savings may shift mix toward U.S./Canada revenue and slightly improve margin assumptions; community access and real-world ORR may support earlier-line adoption assumptions .

Key Takeaways for Investors

  • Q2 2025 was a growth quarter operationally (infusions, cycle-time) but a headline miss vs consensus; the company reaffirmed its FY25 guide, suggesting visibility into 2H demand .
  • Restructuring (> $100M saves) and operational excellence are the core margin story; watch for cost-of-sales moderation and higher margins beginning Q3 .
  • Specialty pharmacy access and community referrals are important near-term demand catalysts, reducing financing barriers for one-time therapies .
  • Canada approval (NOC/c) opens first ex-U.S. revenue stream; UK/Australia/Switzerland reviews provide optionality; EU path continues via resubmission .
  • Real-world ORR (48.8% overall; 60.9% earlier lines) supports earlier sequencing narratives and could expand the addressable market within current label .
  • Proleukin restocking should track Amtagvi utilization; expect stronger 2H contribution as wholesalers normalize ordering cadence .
  • Near-term trading lens: stock likely sensitive to margin progress, community access updates, and 2H clinical readouts (NSCLC, endometrial, IOV-4001) that broaden the lifileucel franchise - .